ダークスーツにストライプのネクタイを着た中年の男性が、ぼやけた企業法務事務所の背景を背にプロフェッショナルなヘッドショットを撮影している。シカゴのトップ弁護士たちのプロ意識を体現している。

ジェームズ・W・マシューズ

パートナー

ジェームズ・W・マシューズ

パートナー

ジェームズ・マシューズは、医薬品・医療機器メーカーを含む多様な企業を対象に複雑なビジネス紛争を扱っており、ライフサイエンス企業やテクノロジー企業を代理して、全国の裁判所や仲裁機関で係争中の商事紛争に頻繁に対応している。訴訟における代理業務に加え、これらの企業が事業展開に伴う訴訟リスクに関して信頼できるアドバイザーとしての役割も担っている。

In the past 20 years, James has acted as lead counsel to generic drug manufacturers and pharmaceutical distributors in some of the most complex and multifaceted litigations pending in courts across the United States. He has also represented these companies as both defendant and plaintiff in commercial disputes, resulting in defense verdicts and plaintiffs’ verdicts and settlements collectively in excess of hundreds of millions of dollars.

Prior to joining Foley, James was a partner at another firm. He also was appointed Special Assistant District Attorney for Middlesex County for an interim period. For two years after law school, he clerked for The Honorable John E. Conway, U.S. District Judge for the District of New Mexico.

James is a member of the Commercial Litigation Practice Group and co-chair of the Pharmaceutical and Other Regulated Drugs Area of Focus within the firm’s Health Care & Life Sciences Sector.

For more than twenty years, James Matthews has tried complex, high-profile cases on behalf of clients in difficult circumstances. He has appeared in state and federal courts around the country, tried cases before judges and juries for plaintiffs and defendants, and won verdicts on behalf of both.  He past trials have included claims under the False Claims Act, federal and state antitrust statutes, and a variety of state unfair competition acts, as well as claims for fraud and breach of contract. In 2009, he obtained the “biggest verdict of the year” in Massachusetts in a patent infringement case. Six months later he “won” a mistrial when an Alabama jury was unable to agree that the pharmaceutical manufacturer he represented (Watson Pharmaceuticals) had defrauded the state of Alabama by submitting fake “Average Wholesale Prices” to Alabama Medicaid. Two years later, James won a unanimous defense verdict in another “AWP” case when a Kentucky jury rejected Kentucky’s identical claims against Watson. In 2015, he took a “pay-for-delay” antitrust cases to trial, representing generic pharma manufacturer Apotex Corp. against industry behemoths Cephalon, Teva, Mylan and Dr. Reddy’s and obtaining — after his closing argument — nine figures in settlements. In 2022 and 2023, James defended Anda, Inc. in two trials accusing it of fomenting and benefitting from the country’s “opioid crisis.” James honed his trial skills as a Special Assistant District Attorney in the Cambridge (Massachusetts) District Court, where he learned that attention to detail was second only to developing strong themes and delivering a clarifying narrative in the toolbox of successful trial lawyers.

代表的な経験

  • Lead national counsel for an international generic drug manufacturer in the generic drug antitrust cases coordinated in the Eastern District of Pennsylvania. Responsible for coordinating claims under federal and state antitrust laws brought by the Attorneys General of most states and purchasers and payors of generic drugs, including Medicaid agencies, wholesalers and distributors, pharmacies, insurers, and consumers.
  • Lead national counsel to several drug manufacturers and a distributor of pharmaceutical products in hundreds of cases pending throughout the United States alleging the creation of a public nuisance arising from the sale and distribution of opioid products. Lead trial counsel for Anda, Inc. in New York state court jury trial and San Francisco federal court bench trial. Coverage of this engagement can be found at: https://www.law360.com/articles/1410255/-overheated-hyperbole-opioid-atty-gets-fiery-in-sf-trial
  • Lead national counsel for a NYSE-listed generic drug manufacturer and its affiliates in government enforcement actions pending in state and federal courts throughout the country. Responsible for coordinating the defense of civil actions under the Federal False Claims Act and analogous state statutes pending in federal court and in state courts in Alabama, Alaska, Idaho, Florida, Hawaii, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Mississippi, Missouri, New York, Oklahoma, South Carolina, Texas, Utah, and Wisconsin.
  • Lead counsel for international generic drug manufacturer in prosecution “pay-for-delay” antitrust action against brand manufacturer and several generic manufacturers, recovering settlements collectively in excess of US $150m on eve of submitting claims to jury following multi-week trial.
  • Lead counsel for international generic drug manufacturer in successful arbitration of complex commercial dispute that injured manufacturer’s reputation in significant government funded health care market.
  • Obtained a US $15.7m patent infringement verdict for NYSE-listed medical device manufacturer, following a seven-day jury trial and two days of deliberations. (This verdict is listed as #1 by Massachusetts Lawyers Weekly in “Top Verdicts of 2009.”)
  • Obtained summary judgment for publicly traded generic drug manufacturer in a claim for breach of contract and unfair trade practices where plaintiffs sought recovery of actual damages equal to US $60m; successfully defended appeal.
  • Represented a NYSE-listed medical device manufacturer in three-week arbitration, obtained US $30m award on behalf of client.
  • Represented a generic drug manufacturer in antitrust action resulting from defendants’ attempted enforcement of invalid and unenforceable patent; obtained settlement resulting in client reporting US $100m gain in publicly filed financial statements.
  • Represented venture capital firm in successful defense of efforts to obtain control of company from entrenched founders/managers.
  • Obtained substantial judgment for internet search engine in multi-day arbitration claiming right to purchase-price adjustment in connection with corporate acquisition.
  • Represented developer in breach of contract and unfair trade practices action, obtained order dismissing counterclaims, and obtained multi-million dollar settlement for client on first day of scheduled trial.

受賞歴と表彰

  • The Best Lawyers in America® in the field of Commercial Litigation (2023)
  • ピアレビュー マーティンデール・ハブベルのピアレビュー評価システムにおける最高評価「AV® Preeminent™」を獲得
  • The Legal 500 for Health Care – Life Sciences
  • Massachusetts Super Lawyers® (2006, 2008-2013)

所属

  • Member of the Massachusetts Bar Association
  • Member of the American and Boston Bar Associations’ Health Care Law, Litigation, and Business Law Sections
  • Member of the Defense Research Institute and its Drug and Medical Devices, Medical and Health Care Law, Construction Law, and ADR Sections
  • Elected to membership in the International Association of Defense Counsel, an invitation-only membership comprised of the world’s leading corporate and insurance lawyers and insurance executives

発表と出版物

  • James is a frequent speaker on topics covering enterprise risk management; litigation prevention, assessment, and management; arbitration of complex business disputes; and depositions.
2025年10月30日 イベント

注視すべき主要な医薬品訴訟動向

医療・ライフサイエンス業界が進化を続ける中、全国の組織は医薬品訴訟の最近の動向に留意すべきです。独占禁止法、知的財産権、集団訴訟、その他の訴訟問題に関わらず、本ウェビナーでは業界で増加傾向にある医薬品の訴訟動向を掘り下げます。
アメリカ合衆国最高裁判所ビル入口の大理石像と柱。その上部には「法の支配の下における平等な正義」と刻まれている——シカゴをはじめとする弁護士たちが知的財産法を守る象徴として認める存在である。
2025年4月18日 フォーリー・ビューポイント

最高裁、特定の身体傷害請求について原告がRICO損害賠償を請求できるとする判決で巡回区裁判所間の見解の相違を解消

米国最高裁判所は、人身傷害に起因する経済的損失について、組織犯罪影響下企業取締法(RICO)に基づく原告の提訴権限を拡大した。
2025年1月28日 イベント

抗体薬物複合体(ADC)の成長は続く:知っておくべきこと

2018年以降、抗体薬物複合体(ADC)関連のライセンス契約は600億米ドル以上と急成長を続けており、2023年だけでも少なくとも18件の契約が成立している。世界のADC市場は近い将来、年間200億~300億米ドル規模に達すると予測されている。
手袋をはめた手が青と紫の細菌培養が施されたペトリ皿を保持している。背景にはぼやけた円形の顕微鏡画像が映し出されている——まるで知的財産法によって保護された革新的な発見のようだ。
2024年12月11日 今日の医療法

抗体薬物複合体(ADC)の成長は続く:知っておくべきこと

過去数年間、ヘルスケア・ライフサイエンス分野と革新的技術分野では取引件数が減少しており、企業もプライベート・エクイティ・ファームも資金の使途を見直している。
抽象的なデジタルアート作品。カラフルで輝く点と線が、濃い青の背景上に渦巻き、波のようなパターンを描き出す。シカゴのトップ弁護士たちに見られるダイナミックなエネルギーを彷彿とさせる、インスピレーションに満ちた視覚表現である。
2024年8月13日 今日の医療法

抗がん剤:抗体薬物複合体訴訟

臨床対象者に製品を提供するための第一歩は、多くの場合特許保護の取得であり、その結果としてADCを巡る訴訟が発生する。
ピペットが、色付きのバーで構成されたデジタルDNA配列解析パターンが印刷されたペトリ皿に液体を分注する。この光景は、バイオテクノロジーの革新と知的財産法の交差点を浮き彫りにしている。
2024年4月29日 今日の医療法

2024年 ヘルスケア&ライフサイエンス分野の主要トレンド

フォーリー・アンド・ラーダーナーの2024年版「ヘルスケア&ライフサイエンス主要トレンド」レポートは、急速に進展する動向を分析し、貴社のビジネスを支援します。